SUNNYVALE, Calif., June 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today that the Tulsa Cancer Institute is the first U.S. center to treat a patient with Accuray's TomoHDA™ System, the latest and most advanced innovation in the TomoTherapy® product lineage designed to treat the full spectrum of cancer patients. Its numerous benefits include streamlined daily 3D CT image guidance for accurate treatment delivery, faster treatment times and the ability to create treatment plans that target the disease and spare healthy surrounding tissues. With the addition of the TomoHDA System, health care providers at the newly opened Tulsa Cancer Institute now have access to the best in cancer fighting technology.
"At Tulsa Cancer Institute, we are dedicated to providing world-class care in every way possible, from a comforting and knowledgeable staff to offering the most advanced treatments which is why we decided to acquire the TomoHDA System," said Daron Street, M.D., Tulsa Cancer Institute. "The flexibility of the TomoHDA System allows our physicians to not only treat common cancers but also tackle more complicated cancers in the most efficient, accurate way possible. The addition of this nimble treatment option will cement the Tulsa Cancer Institute as a leader in cancer care."
The new Tulsa Cancer Institute is Oklahoma's single largest medical facility built by a group of physicians. It boasts the largest number of cancer specialists at one center. Before the Tulsa Cancer Institute opened in June, it was known as Cancer Care Associates where it offered Accuray's TomoTherapy Hi-Art® for years, treating hundreds of cancer patients.
"By upgrading its TomoTherapy System, the Tulsa Cancer Institute has proven its commitment to providing patients with the very best in cancer care as well as its trust in Accuray's advanced technology," said Joshua H. Levine, president and chief executive officer of Accuray. "With the TomoHDA System, the Tulsa Cancer Institute will now be able to create personalized treatment plans that meet the unique needs of more patients, and deliver them accurately and in a shorter time, offering the opportunity for the best clinical outcomes for their patients."
The TomoHDA System sets a new standard for image-guided intensity-modulated radiation therapy (IMRT) with its TomoEDGE™ Dynamic Jaws and VoLO™ Planning technologies. The new TomoEDGE technology reduces treatment time for many patients, while maintaining or surpassing the excellent plan quality achievable with prior TomoTherapy Systems, enabling clinics to treat more patients per day.
The TomoHDA System is also installed at Centre Oscar Lambret in Lille, France where the first patient in Europe was treated earlier this month.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012 & February 6, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated
Rebecca Phillips, Public Relations Manager, +1-408-716-4773, rphillips@accuray.com, or Helen Shik, Accuray Schwartz MSL, +1-781-684-0770, Accuray@schwartzmsl.com
